Skip to content

Clinical effect of probiotics in relieving vaginitis

Clinical effect and mechanism of probiotics in relieving vaginitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060829
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaginitis

Interventions

Placebo group:Placebo
Lactobacillus crispatus group:500 million Lactobacillus crispatus 197
Lactobacillus gasseri group:500 million Lactobacillus gasseri CCFM1201
Compound probiotic group:Lactobacillus crispatus 197 and Lactobacillus gasseri 1201 total 500 million
Compound Probiotics and Prebiotics:Fructo oligosaccharides, Lactobacillus crispatus 197 and Lactobacillus gasseri CCFM1201 (500 million in total)

Sponsors

The Peoples' hospital of Xishan district of Wuxi city
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.The patient was in line with bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC)diagnostic criteria; 2.Women aged 18-65, pre-menopausal and with a history of sexual activity; 3.Good compliance, able to comply with the requirements of clinical trials; 4.The subject or guardian has signed the informed consent and promised to cooperate with the study throughout the study period.

Exclusion criteria

Exclusion criteria: 1.Current or past 3 weeks of vulvar infection, urinary tract infection, sexually transmitted infection (gonorrhea, Trichomoniasis, genital herpes, syphilis, HIV), pelvic inflammatory disease; 2.Pregnant women, pregnant women and lactating women; 3.Allergic constitution such as drug allergy and lactose intolerance; 4.Long-term use of contraceptives and immunosuppressants; 5.Patients with systemic diseases (such as albinism, leukemia, malignant tumor history); 6.Antibiotics, antifungals, topical steroids, or antivirals were taken orally or were being taken orally within 3 months prior to visit (oral or topical); 7.A history of mental illness; 8.Those who had used estrogen or estrogens within 6 months prior to the study; 9.Patients with a history of urogenital surgery.

Design outcomes

Primary

MeasureTime frame
Fecal flora;Blood routine;Vaginal flora;Serum IgA;Serum IgG;Leucorrhea routine;Fecal flora genomics;Vaginal flora genomics;Vaginal secretion metabolomics;

Secondary

MeasureTime frame
Height;Weight;Urine routine;

Countries

China

Contacts

Public ContactQiuxiang Zhang
zhangqx@jiangnan.edu.com+86 13814228495

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026